Sight Sciences (SGHT) announced that Cigna Healthcare (CI) has updated its Glaucoma Surgical Procedure policy to cover both ab interno canaloplasty and goniotomy procedures for the treatment of open-angle glaucoma effective June 15, 2023. “We are pleased that Cigna’s clinical review resulted in expanded coverage of certain non-implant, minimally invasive glaucoma surgery procedures including canaloplasty and goniotomy for its patients,” stated Paul Badawi, Founder and Chief Executive Officer. “As a result of this positive coverage policy, Cigna’s members will have access to the OMNI outflow restorative procedure that addresses all three points of resistance when deemed medically necessary by their ophthalmologist. We believe Cigna’s decision affirms the shift towards safer, less invasive, but more comprehensive surgical inventions, and cements the role that OMNI’s technology serves within the glaucoma treatment paradigm for surgeons and patients.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SGHT:
- Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty and Goniotomy (Trabeculotomy)
- Sight Sciences Announces Addition of New Director Catherine Mazzacco
- Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure (IOP) and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System Technology
- Sight Sciences Announces 12-month Results from the First Minimally Invasive Glaucoma Surgery (MIGS) Comparative Analysis of Real-World Data (RWD) from the American Academy of Ophthalmology IRIS® Registry
- Sight Sciences to Present at the Upcoming Bank of America Securities 2023 Health Care Conference